|
Volumn 109, Issue 3, 2000, Pages 261-262
|
Rhabdomyolysis due to combination therapy with cerivastatin and gemfibrozil [5]
a a a |
Author keywords
[No Author keywords available]
|
Indexed keywords
CERIVASTATIN;
FELODIPINE;
GEMFIBROZIL;
HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;
METOPROLOL;
AGED;
CASE REPORT;
DRUG MECHANISM;
DRUG METABOLISM;
FEMALE;
HUMAN;
HUMAN CELL;
HUMAN TISSUE;
HYPERLIPIDEMIA;
LETTER;
MYOSITIS;
PRIORITY JOURNAL;
RHABDOMYOLYSIS;
RISK BENEFIT ANALYSIS;
RISK FACTOR;
AGED;
ANTILIPEMIC AGENTS;
DRUG THERAPY, COMBINATION;
FEMALE;
GEMFIBROZIL;
HUMANS;
HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS;
HYPERLIPIDEMIAS;
PYRIDINES;
RHABDOMYOLYSIS;
|
EID: 0034663113
PISSN: 00029343
EISSN: None
Source Type: Journal
DOI: 10.1016/S0002-9343(00)00514-3 Document Type: Letter |
Times cited : (60)
|
References (9)
|